Calliditas Therapeutics AB

Developing global, high-value products for patients with significant unmet medical needs in niche indications

Find out more about us

Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Events

Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)

Press releases

May 26, 2020Notice of annual general meeting of Calliditas Therapeutics AB (publ)
May 14, 2020Calliditas publicly files registration statement with SEC for a proposed initial public offering in the United States
May 14, 2020Interim Report Q1, 2020

All press releases

Interim Report Q1 2020

On May 14, 2020, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2020.

Read the report

Calendar

Jun 25, 2020Annual general meeting 2020
Aug 13, 2020Interim report for the period January 1 – June 30, 2020
Nov 12, 2020Interim report for the period January 1 – September 30, 2020